Tags

Type your tag names separated by a space and hit enter

Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes.
J Pediatr. 2003 Dec; 143(6):796-801.JPed

Abstract

OBJECTIVE

To examine the effect of continuous subcutaneous insulin infusion (CSII) therapy on parameters affecting long-term outcome in type 1 diabetes. Study design Height, weight, body mass index, insulin dose, glycosylated hemoglobin (HbA(1C)), and blood glucose data from home meter downloads were collected prospectively for analysis in 51 children (age, 10.7+/-3.1 years, mean+/-SD) throughout the 12 months before and after introducing CSII.

RESULTS

Before pump initiation, HbA(1C) was relatively stable, but it fell to 7.7+/-0.2% (P<.001) within 3 months of CSII and remained decreased (7.9+/-0.1%) at 12 months (P<.01). In contrast, weight standard deviation score increased before CSII (from 0.50+/-0.13 to 0.60+/-0.13, P<.05), but remained unchanged (0.61+/-0.11) in the year thereafter. Although severe hypoglycemia (<50 mg/dL) was reduced in the entire cohort, HbA(1C) improved primarily in young children and teenagers. Comparison of glycemic responders (HbA(1C) <7.5, or a decrease >1% on CSII, n=23) with nonresponders demonstrated no differences with respect to gender, socioeconomic status, weight standard deviation score, body mass index, initial HbA(1C), frequency of hypoglycemia, or number of education visits before CSII.

CONCLUSION

Continuous subcutaneous insulin infusion is effective in lowering HbA(1C) and the occurrence of severe nocturnal hypoglycemia without excessive weight gain in most children with type 1 diabetes. HbA(1C) response to CSII is poorer in preadolescents than in young children or teenagers.

Authors+Show Affiliations

Department of Pediatrics, and the General Clinical Research Center, Medical University of South Carolina, Charleston, South Carolina 29425, USA. willis@musc.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

14657831

Citation

Willi, Steven M., et al. "Benefits of Continuous Subcutaneous Insulin Infusion in Children With Type 1 Diabetes." The Journal of Pediatrics, vol. 143, no. 6, 2003, pp. 796-801.
Willi SM, Planton J, Egede L, et al. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr. 2003;143(6):796-801.
Willi, S. M., Planton, J., Egede, L., & Schwarz, S. (2003). Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. The Journal of Pediatrics, 143(6), 796-801.
Willi SM, et al. Benefits of Continuous Subcutaneous Insulin Infusion in Children With Type 1 Diabetes. J Pediatr. 2003;143(6):796-801. PubMed PMID: 14657831.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. AU - Willi,Steven M, AU - Planton,Jonathan, AU - Egede,Leonard, AU - Schwarz,Sharon, PY - 2003/12/6/pubmed PY - 2004/1/9/medline PY - 2003/12/6/entrez SP - 796 EP - 801 JF - The Journal of pediatrics JO - J Pediatr VL - 143 IS - 6 N2 - OBJECTIVE: To examine the effect of continuous subcutaneous insulin infusion (CSII) therapy on parameters affecting long-term outcome in type 1 diabetes. Study design Height, weight, body mass index, insulin dose, glycosylated hemoglobin (HbA(1C)), and blood glucose data from home meter downloads were collected prospectively for analysis in 51 children (age, 10.7+/-3.1 years, mean+/-SD) throughout the 12 months before and after introducing CSII. RESULTS: Before pump initiation, HbA(1C) was relatively stable, but it fell to 7.7+/-0.2% (P<.001) within 3 months of CSII and remained decreased (7.9+/-0.1%) at 12 months (P<.01). In contrast, weight standard deviation score increased before CSII (from 0.50+/-0.13 to 0.60+/-0.13, P<.05), but remained unchanged (0.61+/-0.11) in the year thereafter. Although severe hypoglycemia (<50 mg/dL) was reduced in the entire cohort, HbA(1C) improved primarily in young children and teenagers. Comparison of glycemic responders (HbA(1C) <7.5, or a decrease >1% on CSII, n=23) with nonresponders demonstrated no differences with respect to gender, socioeconomic status, weight standard deviation score, body mass index, initial HbA(1C), frequency of hypoglycemia, or number of education visits before CSII. CONCLUSION: Continuous subcutaneous insulin infusion is effective in lowering HbA(1C) and the occurrence of severe nocturnal hypoglycemia without excessive weight gain in most children with type 1 diabetes. HbA(1C) response to CSII is poorer in preadolescents than in young children or teenagers. SN - 0022-3476 UR - https://www.unboundmedicine.com/medline/citation/14657831/Benefits_of_continuous_subcutaneous_insulin_infusion_in_children_with_type_1_diabetes_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-3476(03)00579-1 DB - PRIME DP - Unbound Medicine ER -